What Happens After FDA Approval?
Explore what happens after FDA approval, including drug launches, market access, pharmacovigilance, medical affairs, and real-world safety monitoring.
After research, preclinical testing, multiple phases of clinical trials, and a rigorous review process, receiving FDA approval is the next step for a new medication. Receiving FDA approval marks the beginning of an important phase in a drug's lifecycle: commercialization. Commercialization involves ensuring that a product reaches the right patients, is prescribed appropriately, is accessible through insurance plans, and continues to demonstrate safety in real-world use.1 This post-approval period requires collaboration across commercial, medical, regulatory, market access, and manufacturing teams.
One priority following FDA approval is executing a successful launch strategy. Pharmaceutical companies spend years preparing for launch before approval is officially granted. Cross-functional teams align on branding, product positioning, pricing, manufacturing capacity, sales force readiness, and promotional materials. Marketing teams determine how to communicate the product's value to healthcare professionals and patients, medical ensures scientific accuracy, regulatory and legal teams ensure compliance, and market access leads payer engagement. A successful launch strategy helps maximize awareness while supporting appropriate and evidence-based use of the medication.
Another critical component of launch strategy is understanding the competitive landscape. Companies evaluate existing therapies, emerging pipeline competitors, and unmet medical needs to determine how a product should be positioned in a treatment market. Factors such as clinical efficacy, safety profile, route of administration, dosing frequency, and patient convenience influence messaging.2 Commercial teams also identify priority healthcare providers, health systems, and treatment centers that are most likely to prescribe the new therapy during the early stages of launch.3
To support payer negotiations, pharmaceutical companies prepare extensive evidence packages that extend beyond the clinical trial data submitted to the FDA. HEOR teams develop pharmacoeconomic models that demonstrate how a therapy may reduce hospitalizations, improve quality of life, lower long-term healthcare costs, or provide greater value compared with existing treatment options. Please see Justin Shau’s recent article for more information.
Justin Shiau, PharmD
Manufacturers partner with wholesalers, specialty pharmacies, distributors, hospitals, and integrated delivery networks to ensure that products are stored, transported, and dispensed according to strict quality standards. Temperature-sensitive biologics, gene therapies, and cell therapies often require specialized logistics to maintain product integrity throughout the supply chain. Manufacturing facilities continue producing commercial-scale batches under current Good Manufacturing Practice (cGMP) requirements, and quality assurance teams monitor every step of production.
After a medication reaches patients, pharmaceutical companies continue monitoring its safety through pharmacovigilance. Clinical trials involve various patient populations and sometimes with limited sample sizes. In addition, it is infeasible to identify every potential adverse event before FDA approval. Pharmacovigilance teams collect, analyze, and report adverse event data from healthcare providers, patients, published literature, and regulatory agencies.4 The ongoing surveillance helps identify rare side effects, long-term safety concerns, and potential medication errors that may not have been identified during clinical development. Depending on the severity of the findings, actions may include updating prescribing information, updating warnings or precautions, implementing Risk Evaluation and Mitigation Strategies (REMS), distributing Dear Healthcare Provider letters, or, in applicable cases, withdrawing a product from the market.
Medical affairs colleagues play a critical role serving as the scientific bridge between the pharmaceutical company and the healthcare community. Unlike commercial teams, medical affairs professionals focus on scientific exchange rather than product promotion. Medical Science Liaisons engage with HCPs to discuss clinical data, answer complex scientific questions, and gather insights from real-world clinical practice. Please see Brentsen Wolf’s articles discussing What is a Medical Science Liason? and MSL: A Day in the Life for more information. Manufacturers also develop educational programs, CME, advisory boards, scientific publications, congress presentations, and investigator-sponsored research collaborations. This growing body of evidence helps clinicians make informed treatment decisions and supports ongoing conversations with payers, guideline committees, and healthcare institutions.
Brentsen Wolf, PharmD
Brentsen Wolf, PharmD
Ultimately, receiving FDA approval represents a long-term commitment to patients and healthcare providers. Effective launch planning, successful payer negotiations, reliable distribution networks, continuous pharmacovigilance, and comprehensive medical education play essential roles in ensuring that products reach appropriate patients. By working together across multiple functional areas, pharmaceutical companies can turn scientific discovery into meaningful patient care improvement.
References:
- Chen J, Luo X, Qiu H, Mackey V, Sun L, Ouyang X. Drug Discovery and Drug Marketing With the Critical Roles of Modern Administration. Am J Transl Res. 2018;10(12):4302-4312.
- Talabardon JN, Church JE, Okuse M, et al. Incorporating Patient Input into the Target Product Profile. Ther Innov Regul Sci. 2025;59(4):659-667.
- Corvino B, Elsner N, Wagh M, Jaeger J. Rethinking Market Access. Deloitte Insights. 2022.
- Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: Reporting Requirements Throughout a Product's Lifecycle. Ther Adv Drug Saf. 2022;13:20420986221125006.
*Information presented on RxTeach does not represent the opinion of any specific company, organization, or team other than the authors themselves. No patient-provider relationship is created.